Contribution: Industrial Research Assistance Program – Contributions to Firms
9489-9002 Québec inc.
$75,000.00
ARP - Design of targeted cancer therapies based on tumour-specific antibodies.
FY 2025-26 · 2025-04-28
Summary
This project involves integrating tumour-specific antibodies into targeted cancer therapies by conjugating them with a chemotoxic agent. These antibody-drug conjugates will then be evaluated for their ability to kill tumour cells.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Quebec|Québec, Quebec, Canada
Recipient Type
For-profit organization
Business Number
715580148
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2025-04-28 | 2025-26 | $75,000.00 |
| 1 | 2025-04-28 | 2025-26 | $75,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 123 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 123 jours.
Agreement End Date
2026-03-31
Agreement Number
1030052
Agreement Start Date
2025-04-28
Agreement Title
ARP - Design of targeted cancer therapies based on tumour-specific antibodies.
Agreement Title (French)
PRA - Conception de thérapies oncologiques ciblées à partir d’anticorps spécifiques aux tumeurs.
Agreement Type
Contribution
Agreement Value
$75,000.00
Amendment Date
2025-09-04
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project involves integrating tumour-specific antibodies into targeted cancer therapies by conjugating them with a chemotoxic agent. These antibody-drug conjugates will then be evaluated for their ability to kill tumour cells.
Description (French)
Ce projet consiste à intégrer des anticorps spécifiques au tumeurs dans des thérapies oncologiques ciblées en les conjuguant à un agent chimio-toxique. Ces conjugués anticorps-médicaments seront ensuite évalués pour leur capacité à tuer des cellules tumorales.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Beauport--Limoilou
Federal Riding (French)
Beauport--Limoilou
Federal Riding Number
24008
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
715580148
Recipient City
Quebec|Québec
Recipient Country
CA
Recipient Legal Name
9489-9002 Québec inc.
Recipient Operating Name
9Bio Therapeutics
Recipient Postal Code
G1E 3H6
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2025-2026-Q1-1030052
